Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials (Q48577138)

12 February 2018

title

Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials (English)

1 reference

12 February 2018

1 reference

7

Magnus Simrén

1 reference

12 February 2018

author name string

Perjohan Lindfors

1

1 reference

12 February 2018

Peter Unge

2

1 reference

12 February 2018

Patrik Arvidsson

3

1 reference

12 February 2018

Henry Nyhlin

4

1 reference

12 February 2018

Einar Björnsson

5

1 reference

12 February 2018

Hasse Abrahamsson

6

1 reference

12 February 2018

language of work or name

English

0 references

publication date

4 October 2011

1 reference

12 February 2018

The American Journal of Gastroenterology

published in

1 reference

12 February 2018

volume

107

1 reference

12 February 2018

issue

2

1 reference

12 February 2018

page(s)

276-285

1 reference

12 February 2018

Functional bowel disorders and functional abdominal pain

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Non-colonic features of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Quality of life and illness costs in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Long term benefits of hypnotherapy for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Hypnotherapy in severe irritable bowel syndrome: further experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

The treatment of irritable bowel syndrome with hypnotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

An Irritable Bowel Syndrome-Specific Symptom Questionnaire: Development and Validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.340

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.340

1 reference

12 February 2018

1 reference

12 February 2018